NCT03619395 (RiskOp-ACS) is a clinical trial in Acute Coronary Syndrome, sponsored by Parc de Salut Mar.

Who is sponsoring NCT03619395?

NCT03619395 is sponsored by Parc de Salut Mar.

What condition does NCT03619395 study?

NCT03619395 studies Acute Coronary Syndrome, Ischemic Heart Disease.

Is NCT03619395 still recruiting?

NCT03619395 is currently status unknown. Last updated 6 September 2019.

Last reviewed 2019-09-06 · How we verify

NCT03619395: RiskOp-ACS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Risc Optimisation- Acute cor5onary Syndrome

Status unknown Last updated 6 September 2019

What this trial tests

trial in Acute Coronary Syndrome in 150 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
1 July 2020

1 July 2023

Quick facts

Lead sponsor	Parc de Salut Mar
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	150
Start date	1 September 2018
Primary completion	1 July 2020
Estimated completion	1 July 2023
Sites	1 location across Spain

Conditions studied

Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
Ischemic Heart Disease — all drugs for Ischemic Heart Disease →

Sponsor

Parc de Salut Mar — full company profile →

Who can join

18 and older, any sex, with Acute Coronary Syndrome or Ischemic Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the percentage of patients that reach the objective levels of LDL cholesterol, glycosylated hemoglobin and blood pressure recommended by clinical guidelines after an acute coronary syndrome, following strategies of pharmacological optimization based on algorithms. The investigators hypothesize that the use of algorithms designed and protocolized within a cardiac rehabilitation program after an ACS to optimize pharmacological treatment is effective and safe to improve the control of risk factors in patients with high cardiovascular risk.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome.
Ruiz-Bustillo S, Badosa N, Cabrera-Aguilera I, Ivern C, et al · · 2022 · cited 3× · PMID 35958430 · DOI 10.3389/fcvm.2022.916031
Prognostic Utility of a New Risk Stratification Protocol for Secondary Prevention in Patients Attending Cardiac Rehabilitation.
Cabrera-Aguilera I, Ivern C, Badosa N, Marco E, et al · · 2022 · cited 3× · PMID 35407518 · DOI 10.3390/jcm11071910

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting

Other Parc de Salut Mar trials

Trials by the same sponsor.

NCT06163235 — Efficacy of a Mobile Application and Semi-attendance Program in Bariatric Surgery · NA · not yet recruiting
NCT07223450 — A Study on Oral and Intranasal Forms of Oxycodone in Healthy Volunteers Using Pharmacokinetic Modeling · Phase 1 · completed
NCT07504913 — Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41 · recruiting
NCT06806072 — BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY · NA · not yet recruiting
NCT04084795 — Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03619395 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Parc de Salut Mar
Last refreshed: 6 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03619395.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing